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Abstract
The purpose this study was to develop a psychometrically sound paper-n-pencil
questionnaire for the measuring and diagnosing of anosognosia in Alzheimer’s disease
(AD). Anosognosia is defined as the lack of awareness one has towards one’s own state.
It manifests within AD as an unawareness of symptoms the individual is experiencing.
The initial 43-item questionnaire was administered to 67 AD patients (age: u = 72.66, SD
= 3.40), with 41 females and 26 males. A Cronbach’s-alpha of 0.89 was obtained
showing the questionnaire had excellent internal reliability.
The 43 items in the original questionnaire were reduced to 10 using the internal
reliability analysis. The 10-item questionnaire was administered to a new group of 83
AD patients (age: u = 75.83, SD = 3.83), with 58 females and 25 males. Internal
reliability of the new questionnaire remained high with an obtained Cronbach’s-alpha of
0.87. Correlations between the sample population 10-item questionnaire score and the
Mini Mental State Exam (r = -0.24, p < 0.05) and Geriatric Depression Scale (r = -0.30,
p < 0.05) showed a low but significant correlation. The 8-Point Clock Drawing (r = 0.04, p > 0.05), and Zarit’s Caregiver Burden Scale (r = 0.04, p > 0.05) showed no
correlation. Using 19 of the patients a one-way Intraclass Coefficient (ICC) was used to
determine inter-rater agreement (alpha = 0.63). Twenty-one of the patients were used for
the purpose of test-retest and resulted in a Pearson-r correlation of r = 0.70 (p < 0.000).
Forty-three normal subjects were enrolled in the study (age: u = 73.95, SD =
3.90) with 23 females and 20 males. Using the normals mean + 2SD a cutoff score of 12
was obtained as the point where an AD patient was diagnosed as having anosognosia.
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Using the cutoff value there were 42 AD patients who had anosognosia which was 51%
of the sample population.
The questionnaire was found to be reliable though further studies would be
needed to confirm the results by expanding the sample size and using more generalized
inclusion criteria. Nevertheless, the questionnaire showed little relationship to the other
questionnaires administered during the study. This helps to show the questionnaire is
measuring a unique phenomenon which is not related to other standard diagnostic
questionnaires used with AD patients.
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1. LITERATURE REVIEW
1.1 Alzheimer’s disease
In 1901 Auguste D was a 51-year-old patient who was committed to the Frankfurt
Asylum with what was considered to be unusual symptoms (Schneider & Dagerman,
2004). Alzheimer, who was a physician on staff, became fascinated with Auguste's state
and followed her slow cognitive decline until her death 5 years later. Alzheimer had her
brain sent to Kraeplin's laboratory in Munich where the two examined the brain using
new staining techniques to identify a large amount of amyloid plaques and neurofibrillary
tangles within the brain tissue (Small & Cappai, 2006). The same year Alzheimer
presented both his pathological and clinical symptoms of presenile dementia noting
Auguste’s memory loss, disorientation, hallucinations, and untimely death. Later the
disease was unintentionally named when Kraeplin used the term “Alzheimer’s disease” in
a textbook he authored (Morris & Salmon, 2007).
Alzheimer’s disease (AD) has become the most common form of dementia,
representing more then 60% of today’s current dementia diagnoses (Ferri, et al., 2005). It
is estimated that in 2000 over 4 to 4.5 million people in the United States were suffering
from AD, and it is estimated that this number may triple or quadruple by 2050 (Kawas,
2003). In 2006, the worldwide estimate for the prevalence of AD was 26.6 million. This
number is also expected to increase in relation to the United States estimate, with 1 in 85
persons in the world being afflicted by the disease ((Brookmeyer, Johnson, ZieglerGraham, & Arrighi, 2007).
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AD has a slow onset with the disease classified into 3 stages; mild, moderate, and
severe. Mild AD is characterized by small changes in normal cognitive functioning such
as the ability to remember recent events or information (Peterson, 2007). As the disease
progresses into the moderate stage the individual’s cognitive functions deteriorate to
where there is a decrease in the level of independence in relation to activities of daily
living (ADL). The individual may also require greater assistance in performing more
cognitively challenging tasks. The disease will then progress into the severe stage.
During the severe stage an individual looses the ability to function on a day-to-day basis.
Symptoms can include inability to recognize family members, problems speaking,
performing simple daily activities, or changes in personality or behaviors. The 3 stage
model is most commonly used though there have been other scales introduced in an effort
to stage AD, such as Reisberg’s (1982) subjective 7 stage Physician-rated questionnaire
called the Global Deterioration Scale (G.D.S.) (Table 1).
Table 1. Global Deterioration Scale (G.D.S.)
7 Stage of decreasing ability
Stage 1: No cognitive decline
Stage 2: Very mild cognitive decline
Stage 3: Mild cognitive decline
Stage 4: Moderate cognitive decline
Stage 5: Moderately severe cognitive decline
Stage 6: Severe cognitive decline
Stage 7: Very severe cognitive decline
Reisberg B, et al. Am J Psychiatry. 1982;139:1136-1139.
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The widely accepted diagnosis criterion for probable AD is the National Institute
(McKhann, et al., 1984). The criteria states that dementia needs to be established by
clinical examination and documented by cognitive tests, confirmed by
neuropsychological testing, contain at least two areas of cognition deficit, demonstrate
progressive worsening of symptoms, have an onset between 40 and 90 years of age, and
an absence of any other systematic or brain disease capable of producing dementia
(Cummings, 2007).
Though the previous standard has been used for over 2 decades, today it is
common place for a PET scan to also be performed in order to differentiate between AD
and frontotemporal dementia (FTD) (Corey-Bloom, et al., 1995). The reasoning for a
PET scan is that FTD will often meet the diagnostic criteria for AD (Varma, et al., 1999).
The use of a PET scan helps to determine if there is severe hypometabolism in the
frontotemporal area of the brain which is an identifying feature of FTD and thereby will
rule out AD.
As with staging, the NINCDS-ADRDA is not the only existing diagnostic criteria (Table
2). The International Classification of Disease, 10th revision (ICD-10) criteria includes
the presence of dementia, insidious onset, slow deterioration of cognition, absence of
clinical or laboratory evidence of a systematic illness or brain disease that can induce
dementia, and the absence of a history of sudden onset of neurological signs indicative of
focal brain injury. The Diagnostic and Statistic Manual of Mental Disorders, 4th edition
(DSM-IV) (APA, 1994) and Diagnostic and Statistic Manual of Mental Disorders Revised, 4th edition (DSM-IV-TR) (APA, 2000) requires a gradual onset and a
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Table 2. Three Criteria for AD Diagnosis

Characteristics
Memory decline
Thinking impairment
Aphasia, apraxia, agnosia or
disturbed executive functioning
Impairment of at least one nonmemory intellectual function
Dementia established by
questionnaire
Dementia confirmed by
neuropsychological testing
ADL impairments
Social or occupational impairment
Decline from previous level
Onset between the age of 40 and 90
Insidious onset
Slow deterioration
Continuing deterioration
Absence of clinical or laboratory
evidence of another dementing
disorder
Absence of sudden onset
Absence of focal neurological signs
Absence of substance abuse
Deficit not limited to delirious
period
Absence of another major mental
disorder

ICD-10
+
+
-

DSM-IV
+
+

NINCDS-ADRDA
Probably AD
+
-

+

+

+

-

-

+

-

-

+

+
+
+
+
+

+
+
+
+
+

+
+
+
+
+

+
+
+

+
+

+
+
+

-

+

-

Cummings, J. (2004). Definitions and diagnostic criteria. In Clinical
Diagnosis and Management of Azlheimer's Disease. 3nd Edition. Ed. S.
Gauthier. Martin Dunitz, London.
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continuing cognitive decline, as well as the absence of other neurological disorders,
systematic conditions, or substance abuse sufficient to induce dementia. Furthermore, the
condition cannot occur during a delirium and must not be attributable to a major
psychiatric disorder.
Unlike the ICD-10 and DSM-IV, the NINCDS-ADRDA criteria does not rely on
activities of daily living as a diagnostic criteria, but instead uses it as supportive
information. It is considered to be a weakness by some since it can cause the disease to
be under diagnosed. However, the NINCDS-ADRDA also has its strength since its
criteria excludes sudden onset which is not a conventional occurrence with AD. Also,
unlike the DSM-IV criteria, it does not exclude patients who have substance abuse,
depression, or schizophrenia (Cummings, 2007).
There are 3 possible diagnostic categories for AD: definite, possible, and probable
(Table 3). A definite diagnosis requires the NINCDS-ADRDA criteria to be met together
with histopathologic evidence of AD through autopsy or biopsy (Schachter & Davis,
2000). Probable AD requires the dementia to have onset between 40 and 90 years of age;
that it be established by clinical examination and documented by cognitive testing;
contain deficits in two or more areas of cognition; have a progressively worsening
cognitive function; be devoid of any disturbance of consciousness; and the absence of
any systematic or brain disease capable of producing a dementia syndrome. Lastly, the
criteria for Possible AD includes an atypical onset, presentation, or progression of a
dementia syndrome without a known cause; the presence of a systematic or other brain
disease capable of producing dementia, but not thought to be the cause of the dementia;
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Table 3. Diagnosis Categories for AD
Definite AD
•
•

Clinical criteria for probable AD.
Histopathologic evidence of AD (autopsy or biopsy).
Probable AD

•
•
•
•
•
•
•

Dementia established by clinical examination and documented by mental
status questionnaire.
Dementia confirmed by neuropsychological testing.
Deficits in two or more areas of cognition.
Progressive worsening of memory or other cognitive functions.
No disturbance of consciousness.
Onset between 40 and 90 years of age.
Absence of systematic or brain disease capable of producing a dementia
syndrome.
Possible AD

•
•
•

Atypical onset, presentation, or progression of a dementia syndrome without a
known cause.
Presence of a systematic or other brain disease capable of producing
dementia, but not thought to be the cause of the dementia.
Gradually progressive decline in a single intellectual function in the absence
of any other identifiable cause.
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and the gradual but progressive decline in a single intellectual function in the absence of
any other identifiable cause (Lopez , et al., 2000).
1.2 Pathogenesis of AD
AD is considered to be a multifactorial disease (Blass 1993). Associated with the
disease are genetic and environmental factors which contribute to inflammatory
responses in the brain and the eventual loss of neurons which ultimately lead to the
manifestation of AD. Most notable changes to the brain and what are believed to be the
primary cause of AD is the presence of beta amyloid plaques and neurofibrillary tangles
(NFT).
Beta amyloid plaques are formed from an abnormality with the functioning of
Amyloid precursor proteins (APP). APP is normally found in the brain and essential to
the brain’s development and repair. After use APP is broken down into 37-amino-acid
segment and is recycled to create more APP (William & Shankle, 2005). Within the AD
patient APP incorrectly breaks down and creates 40- and 42-amino-acid fragments.
Called beta amyloid plaques, the fragments are not reused and begin to collect within the
brain into protein accumulations called BA42 complexes which cause neuronal death
(Selko, 2004).
NFT is a cytoskeletal abnormality found in AD, though it is not unique to the
disease itself (Terry & Katzman, 1983). NFT appear to be created by the abnormal
accumulation of Tau proteins which are essential to maintaining the shape and structure
of the neuron. Due to a mutation of a gene on chromosome 17 the Tau proteins begin to
twist causing a neuron’s axon to become misshapen (William & Shankle, 2005). The
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malformed proteins block the flow of molecules from the cell body to the outer regions of
the cell, eventually causing the death of the neuron.
It is uncertain how the two processes are related and it is currently believed AD is
the result of multiple factors which produce neuronal death. Whether beta amyloid
plaques or NFT are the initial trigger, or if they are independent occurrences causing the
disease is still in debate (Belanger, Pearson, & Poirier, 2007).
1.3 Risk Factors
Age is considered the greatest risk factor for developing AD. Ten percent of
people over the age of 65 have AD with the risk doubling every 5 years thereafter
(“National Institute on Aging”, 2006). Some individuals inherit AD (Familial), though
this occurs in less then 1% of AD cases with onset occurring before the age of 65.
However, almost all people with Down syndrome start to show AD associated changes to
the brain after age 40 with onset occurring in their 50s or 60s (Black, Patterson, &
Feightner, 2001).
Gender has not been found to be a risk factor among AD patients in the United
States, however females in Europe and Asia have are reported to be at a higher risk then
males (Feinberg et al., 2000). Though the reasons are not yet fully understood, some
investigators believe the cause may be the greater longevity of woman, difficulty in
diagnosing males since there is a higher prevalence of cerebrovascular disease with men,
and unexpected hormonal effects brought on by menopause and low testosterone levels
(Belanger, et al., 2007).
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Lower education level has been linked to an increased risk in AD (Karp et al.,
2004), while other studies failed to show an association, or an association was only
demonstrated within subgroups. (Letenneur et al., 2000). It is hypothesized that higher
level of education creates improved abilities in thinking, learning, and memory which
result in the constantly challenged brain creating a cognitive reserve. The reserve allows
the brain to adapt to the damages caused by AD (Roe, Xiong, Miller, & Morris, 2007).
An analogy often used is how the body accrues benefits to fight disease when regular
physical exercise is performed.
Other additional documented risk factors include chronic inflammatory
conditions, clinical depression, strokes, high cholesterol, high blood pressure, stress,
obesity, and toxins (Ampuero et. al., 2008). Though documented they have note been
shown to be significant risk factors, but are believed to contribute to the overall chance of
being afflicted with the disease.
1.4 Anosognosia and Alzheimer’s disease
The term commonly used for AD awareness deficits is anosognosia, though the
term is also used to describe both neurological and psychological conditions. Gabriel
Anton first recorded a description of anosognosia in 1893 (McGlynn & Schacter, 1989).
Gabriel reported a patient’s unwavering belief that his daughter was constantly lying by
his left side. The term , however, was also applied to a disorder by Babinski (1914) when
describing the lack of awareness in two hemiplegic patients that denied their left
hemiplegias after suffering a stroke (Feinberg et al., 2000).
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Anosognosia as described by Babinski is directly referring to a lack of awareness of
motor deficits, and not to any cognitive deficit within the patient (Anderson & Tranel,
1989). Unfortunately, the term has come to identify a variety of conditions in which the
patient experiences a lack of awareness and this has been partially responsible for the
many hypotheses relating to the cause of the disorder. As previously mentioned
anosognosia was originally associated with left-hemisphere neglect. Currently it has also
been used to describe the denial of symptoms in cognitive disorders and more recently it
was used to refer to a parent, caregiver, or teacher’s inability to recognize the cognitive
decline of children they care for (Butler & Light, 2003).
Within the AD population, anosognosia was first used to describe the cognitive
deficits of an individual. Physicians have widely identified a lack of awareness among
patient’s suffering from Alzheimer’s disease. The most noticeable deficit is a patient’s
ability to recognize their cognitive limitations; however, the patient may also fail to
realize changes that occur in their behavior, as well as physical limitations they
experience. With these deficits in mind, investigators and clinicians have been actively
studying the physiological, psychological, and maintenance issues of AD patients who
present symptoms of anosognosia. Present research has shown the number of AD
patient’s suffering from anosognosia is approximately 20% (Migliorelli, et al., 1995),
though the number is believed by some investigators and clinicians to be as high as 75%
(Antoine et al., 2004).
Anosognosia can have a direct effect on the diagnosis, intervention, treatment,
and management of patients inflicted with the AD (Cotrell, 1997). Important to the care
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of the AD patient is the ability of clinicians, staff, and social workers to be able to guide
caregivers to effective means of managing patient activities. Giving the caregiver an
insight into the extent of anosognosia being experienced by the patient can help to
alleviate caregiver stress by giving them information as to why a patient may not be able
to understand what they can and can not do. By doing so the quality of life for the patient
and caregiver can be enhanced.
The diagnosis of anosognosia in hemiplegic patients is simple since it requires the
physician only to observe a patient’s response to a number of straight forward questions
regarding the left side of the patient’s environment (McGlynn & Schacter, 1989).
Ramachandran and Blakeslee (1998) presented a clear example with his description of
Mrs. Dodds, a patient who had a stroke that resulted in paralysis of her left arm.
Whenever she was asked questions to perform an activity that required the use of her left
arm, she would give a response that allowed her to avoid acknowledging her paralysis.
The response would center on her unwillingness to perform a task she had already been
asked to do, or that she was too tired to perform the task.
The diagnosis in the preceding case was readily made; however, the etiology of
anosognosia is far more complex and not greatly understood (McGlynn & Schacter,
1989). In some cases the patient may believe they are actually performing a task
requiring the use of a paralyzed limb, such as clapping their hands together, when in
reality the affected limb is not responding at all. Furthermore, there have been
observations of patients who will altogether deny the ownership of their affected limbs,
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claiming it belongs to someone else even though the person may not be present in the
room or no longer alive.
There have been a number of theories to explain anosognosia in the hemiplegic
patient with most falling into two categories (Ramachandran and Blakeslee, 1998). The
first category involves the Freudian concepts of coping. It occurs when a patient is
unable to come to terms with their illness and they attempt to cope with the situation by
relying on the defense mechanism of denial. The second category takes on a neurological
view with the denial being a direct consequence of left-hemisphere neglect. When
anosognosia occurs it is in relation to damage to the right hemisphere of the brain which
supports the neurological theory.
The cognitive deficit seen in AD patients with anosognosia involves denial of
common AD symptoms such as memory and executive functioning impairment.
Executive functioning consists of, but is not limited too, actions involving planning,
decision making, error correction, or situations to resist a strong habitual response. One
of the earliest empirical studies on AD anosognosia was performed by Reisberg and
colleagues (1985). The study reported significantly less awareness of cognitive deficits
in moderate to severe AD cases when compared to mild cases. The investigators
proposed that anosognosia may be the result of a defense mechanism that attempts to
protect the individual from knowledge of their illness and thereby avoiding possible
depression. To explore this idea, there have been numerous attempts designed to
examine the correlation between patient severity of AD and depression. Feher and
associates (1991) reported a weak negative correlation between anosognosia and
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depression, while in a separate study by Sevush and Leve (1993) reported a significant
negative correlation between the two. A third study by Reed and associates (1993) failed
to find any significant correlation between depression and anosognosia in their subject
population.
Other investigators have moved away from searching for a psychological
mechanism for anosognosia and instead looked at neurological damage in the frontal
lobe. In separate studies conducted by Lopez and associates (1994), and Michon and
associates (1994), AD patients with anosognosia were found to have significantly greater
cognitive deficits when compared to AD patients without anosognosia. Both
investigators suggested frontal lobe damage as being the cause of the anosognosia since
the anosognosia group did worse at performing tasks related to tapping into frontal lobe
functions. The frontal lobes are involved in problem solving, spontaneity, memory,
language, judgment, impulse control, and social behavior. Damage to the region may
cause the patient not to process fully the ramifications of actions they take. There has
been difficulty in replication of the studies. The reason may be caused by many studies
relying on a cognitive domain relating to items of memory, or spatial and temporal
orientation, while others included a behavioral domain which includes irritability,
selfishness, inappropriate emotional display, and lack of inhibition (Starkstein, Sabe,
Chemerinski, Jason, & Leiguarda, 1996).
In 1996 Starkstein and associates addressed the issue of differing domains by
examining 186 AD patients. The patients were administered the Anosognosia
Questionnaire-Dementia (AD-Q) and a battery of tests geared towards determining their
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cognitive and behavioral states. To access behavior, subjects were given the clinical
interview for axis 1 DSM-III-R diagnosis (SCID), the Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAM-A), Bech Mania Scale, Pathological Laughing and
Crying Scale (PLACS), Apathy Scale, Irritability Scale, Dementia Psychosis Scale
(DPS), and Functional Independence Measure (FIM). To access cognitive abilities the
Mini-Mental Status Examination (MMS), Raven’s Progressive Matrix (RPM), Wisconsin
Card Sorting Test, Controlled Oral Word Association Test, Digit Span, Buschke
Selective Reminding Test, Token Test, Block Design, and Similarities Test were
administered. The results indicated that cognitive deficits were positively correlated with
severe intellectual decline, a higher frequency of delusions, severe apathy, and a decrease
in depression. Lack of awareness of behavioral changes positively correlated with lack of
inhibition scores and severe pathological laughing. An important finding was a very
weak positive correlation between lack of behavioral awareness and neuropsychological
test scores. The authors point to these findings as further evidence to show that
anosognosia within AD has two distinct domains with very different mechanisms.
Concurrent studies performed with neuropsychological questionnaires on AD
patients with anosognosia have shown significantly more deficits related to the frontal
lobe (Lopez, Becher, Somsak, Dew, and DeKosky, 1993); (Michon, Deweer, Pillon,
Agid, and Dubois, 1994) when compared to AD patients without anosognosia. These
findings suggest AD anosognosia is the result of damage to the frontal lobes, and this
view has become readily accepted by many investigators although these studies could not
be replicated (Bech, Kastrup, and Rafaelsen, 1986).
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By far, the greatest problem relating to the study of anosognosia in AD patients
stems from the heterogeneity of the population. The progression of AD has a highly
variable duration of disease, rate of cognitive decline, and appearance of symptoms.
Studies designed to determine correlations between phenomena within AD and
anosognosia often fail due to the variability found within the population. An example of
the problem was identified in a study performed on AD patients by Feher and associates
(1991). Thirty-eight AD patient were administered a battery of memory tests which
included the Logical Memory (LM) and Paired Associate (PA) module from the
Wechsler Memory Scale, and the Benton Visual Retention Test (BVRT). They
determined the level of denial by administering a standard memory questionnaire to the
patient and caregiver. The investigators were surprised to find only weak correlations
between a patient’s level of denial and the severity of memory impairment.
Reed and associates (1993), and Michon and associates (1994), reported similar
findings when studying AD and anosognosia. Reed and associates found the ability of
mild and moderate AD patients to accurately report personal memory impairments had no
direct relationship to the severity of their dementia. Michon compared the memory of
AD patients with mild and moderate dementia and found a high variability in self rated
memory skills within each group. Michon suggested that the variability was due to a
defense mechanism caused by the patient’s depression about their illness; however, he
quickly points out that none of the study patients were diagnosed with depression. He
further suggests that the amount of information an individual patient receives from
caregivers and family may lead to a greater recognition of their deficits. Supporting this
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idea are studies suggesting an AD patient’s awareness of deficits may be influenced by
the treatments they receive, the quality of available psychiatric services and social
support, and the amount of illness related information they obtain (Johnson & Orrell,
1995). It has been suggested indirect interventions can help a patient to recognize the
facets of their illness.
Feher (1991) pointed out that AD patients have the ability to learn more complex
insight in regards to self-awareness. Insight is retained in many AD patients without
regard to the level of diseases severity. Given the variability of anosognosia in the
population, some individuals are more likely than others to benefit from awareness
enhancing interventions. The specific effects anosognosia is having on the patient’s
ability to understand their personality, behavior, and cognitive abilities need to identified
and understood before clinicians are able to determine if a patient is likely to benefit from
an awareness intervention.
Another difficulty with insight intervention is the possibility that a newly acquired
insight will be bound to a specific outcome of one of the diseases symptoms (Glisky &
Schacter, 1987). The overall learned insight might be confused or lost if the status or
environment of the associated symptom changes. A patient who is helped to gain insight
into not wandering away from the house may not maintain the behavior when moved to a
new living location. Butters and associates (1993) provide an opposing point of view
stating that repetition of tasks, ideas, and concepts can cause successful learning in most
memory-impaired patients. Their findings showed a positive correlation between
increased repetition of tasks and the amount of learning in patients. These authors also
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assert that a task must be meaningful to the individual patient for successful learning to
take place.
Regnier and Pynoos (1992) provide guidelines to allow caregivers, working along
with clinicians, to create an environment designed to foster insight in elderly patients
with dementia. In this scenario, the caregiver develops different strategies to cue
behaviors important to everyday activities of the patient. Examples of this strategy
include placing the patient’s medication next to meals or making sure a comb is easily
visible when the patient stands at the bathroom sink. Though not a solution to all the
problems encountered with the AD patient, the situation exemplifies the need for
caregiver education to identify anosognosia and is important as they will be directly
involved with the tasks necessary to try and help a patient compensate for their lack of
awareness (Barco, Crosson, Bolesta, Werts, & Stout, 1991).
There is still a lot to be understood about AD anosognosia. Currently there is no
gold standard for measuring anosognosia. Investigators and clinicians have used
different means to gauge anosognosia from non-validated questionnaires of their creation,
modified versions of other scales, or basing the degree of anosognosia buy using clinician
observation (Cotrell, 1997). Though it is only part of the disease its can have a
significant impact on the quality of life of the patient and caregiver. The ability of a
caregiver and clinician to manage the patient relies heavily on the patient being aware of
the presenting symptoms and careful monitoring can improve the quality of life for the
AD patient, caregiver, and family. Necessary to accomplish this goal is easily
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administered questionnaires capable of capturing the broad effects of the awareness
deficit and producing results that can be easily explained to a caregiver.
1.5 Driving, Dementia, and Alzheimer’s disease
In 1999, there were more than 18.5 million licensed drivers over the age of 65,
comprising 10 percent of all licensed drivers (U.S. Department of Transportation, 2000).
This number is projected to grow to over 17 percent by the year 2020 (Marottoli, 2000).
However, it is believed that the proportion of elderly drivers will be even greater than this
estimate due to the increasing number of women drivers this group. Elderly drivers
travel fewer miles than any other age group, on average less than 2600 miles per year
after age 80 (Dubinsky, Stein, & Lyons, 2000). However, per mile driven, elderly drivers
have higher rates of traffic violations, collisions, and fatalities than all age groups over
age 25 (Beers & Berkow, 2000).
While society recognizes the importance of maintaining the autonomy and
independence for the elderly that are granted by driving privileges, there are inherent
risks associated with driving that increase with age. According to the NHTSA, in 2000,
six percent of all people injured in traffic accidents were elderly. They made up 13
percent of all traffic fatalities and 12 percent of all vehicle occupant fatalities. Most
traffic fatalities involving the elderly occurred during the daytime (81 percent), on
weekdays (71 percent), and involved another vehicle (76 percent). In two-vehicle
crashes, the car driven by the elderly individual was more than three times as likely to be
struck and more often involved maneuvers such as yielding right-of-way, heeding stop
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signs or red lights, and negotiating intersections (U.S. Department of Transportation,
2000); (Beers & Berkow, 2000).
Driving performance among older adults is affected by numerous age-related
changes in physiology and cognition. Medical conditions and medications can affect
vision, hearing, vehicle control, and attention. However, the single most important
medical diagnosis affecting driving performance has been dementia, particularly AD,
where crash rates as high as three times that of the general elderly population have been
(Dubinsky, et al., 2000).
Generally, in the case of medical diagnoses such as diabetes, heart failure or
stroke, it has been found that the elderly often compensate well for their physical
limitations and will voluntarily limit or relinquish their driving privilege (Carr, 2000).
This has not been so with AD patients in whom the presence of anosognosia can
adversely impact a patient’s ability to recognize poor or worsening driving performance.
Rebok and associates (1994) stated that patients with AD tend to continue driving until an
accident occurs or someone forcefully intervenes. Dubinsky and colleagues stated that the
mean duration of dementia to onset of first crash was 4.0 years with an average MMSE
score of 19.9 at the time of crash.
Rebok provided evidence for the role of anosognosia as a contributor to high
accident rates with the use of self-appraisal mechanisms. These showed that while
controls and AD patients were identical in rating their driving capabilities, the AD group
performed significantly worse. AD patients tended to underestimate the severity of their
impairments and the skills necessary to avoid accidents while driving.
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1.6 Neuroimaging and AD Related Anosognosia
As early as 1995 research was performed using PET, MRI, and SPECT imaging
techniques in an attempt to discover brain regions involved in the occurrence of
anosognosia (Vogel, Hasselbalch, Gade, Ziebell, & Waldemar, 2005). When
investigating the ability of subjects to self-asses their cognitive and behavioral activities
the temporoparietal junction has been reported to have high activation (Salmon, et al.,
2006); (Ruby & Decety, 2001); (Vogel & Luck, 2002). However, during the last decade
more studies have identified other areas of the brain with potential relationships to “selfawareness”. These differing results leave open the question of which areas of the brain is
responsible for anosognosia.
In 2005 Vogel and associates reported a decreased activity in the right inferior
cortex using SPECT imaging techniques. Stanonik (2002) identified other potential
regions which included hypoactivation in the right prefrontal lobe and anterior cingulated
cortex in subjects with anosognosia.
The cause of these apparently conflicting results is unknown although it has been
suggested the diverse methodology among studies may be responsible. The various
questionnaires being used to measure anosognosia may be the cause. Several
questionnaires have appeared in multiple studies, but they have not gone through
thorough psychometric testing, while others are created specifically for a study and have
little to no testing of reliability or validity.
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2. METHODS
2.1 OVERVIEW OF COLE ANOSOGNOSIA SCALE FOR ALZHEIMER’S
DISEASE (CAS-AD)
The development of the Cole Anosognosia Scale for Alzheimer’s disease (CASAD) had two phases. The first was the development of a 43-Item questionnaire which
was administered to patients and caregivers. Collected along with the 43-Item
questionnaire were the Mini Mental State Exam (MMSE) and Geriatric Depressions
Scale (GDS). The two questionnaires were part of normal routine exams that every
patient undergoes at the clinic where subjects were enrolled.
Once sufficient data was collected (n>50) the 43-Item questionnaire was reduced
to 10 items using Cronbach’s alpha (Cronbach, 1951) to perform item reduction. The
resulting questionnaire was administered to a new sample of patients along with the
MMSE, GDS, and Clock Drawing Task (CDT-8), Trail-Making Task: Part B (TMT-B).
The caregivers were administered the new 10-item questionnaire and the Zarit’s
Caregiver Burden Scale (ZCBS).
Lastly, the 10-items scale was administered to normal subjects to determine a
cutoff score for determining individuals who had anosognosia. The cutoff score was then
used to identify the AD patients with anosognosia and analysis performed on their TMTB when compared to AD patients without anosognosia.
The methods to analyze the data collected are described in the following sections.
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2.2 SUBJECT SELECTION
2.2.1 Inclusion/Exclusion Criteria for AD Subjects
The inclusion criteria used for subjects of the 43-item and the 10-item
questionnaire were identical. The patient must have had a willingness to participate,
diagnosed with AD, scored between 15 and 24 on the MMSE, and had no history of other
dementias or any severe psychological disorders, and at least one primary caregiver with
the willingness to participate. A patient would be excluded from the study if all primary
caregivers had any history of dementia or any severe psychological disorders. All AD
patients included in the study were current patients at the Cole Neuroscience Center,
University of Tennessee Medical Center, Knoxville, Tennessee. The patients completed
all questionnaires during regular visits to the Cole Neuroscience Center Alzheimer’s
Clinic days.
2.2.2 Inclusion/Exclusion for Normal Subjects
The inclusion criteria for the normal subjects were a willingness to participate,
scored between 27 and 30 on the MMSE, no history of other dementias or any severe
psychological disorders, and at least one caregiver willing to participate. A subject
would be excluded the caregiver acting as a caregiver had a history of dementia or severe
psychological disorders. All normal subjects included in the study were obtained from
the Cole Neuroscience Center or Sleep Disorder Center (University of Tennessee
Medical Center, Knoxville, Tennessee).
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2.3 STANDARD QUESTIONNAIRES
2.3.1 Mini Mental Status Exam (MMSE)
The accepted gold standard in cognitive testing for dementia is the MMSE
(Folstein, Folstein, & McHugh, 1975)). The MMSE has a score ranging from 0 to 30
point and tests the following categories; orientation (10 points), registration (3 points),
attention (5 points), recall (3 points), language (8 points), and visuospatial (1 point)
abilities. The questionnaire must be administered by an examiner who asks a series of
questions in a specific order. The orientation category has 10 questions about time, date,
and locations. Each correct answer is scored 1 point. Registration requires the patient to
repeat 3 words the examiner says with 1 point scored for each (this can be done multiple
times until the patient answers correctly, though scoring is only done on the first
response). Attention requires the patient to concentrate on spelling a 5 letter word
backwards or count from 100 backwards by decrements of 7 until they reach 65. One
point is scored for each correct response. Recall is tested by asking the patient to repeat
the 3 words used in the registration part of the exam with each correct answer scoring 1
point. The language part is a series of 8 questions ranging from naming items to writing
a sentence and is worth 8 points total. Finally, the last question asks the patient to copy a
design of overlapping figures to test visuospatial ability and is worth 1 point if the patient
draws figures resembling the ones on the exam and they overlap appropriately.
2.3.2 Geriatric Depression Scale (GDS)
The GDS is a 30 item questionnaire developed to identify mild and severe
depression in the elderly. The questionnaire has been shown to have a strong sensitivity
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and specificity (sensitive = 84%, specificity = 95%) (Yesavage, et al., 1982). Each of the
30 items is a simple sentence asking about a person’s current satisfaction with life. The
GDS is a self-administered questionnaire with each question being answered by circling
“no” or “yes”. A question has a score of 1 depending on the answer circled (“yes” is
worth 1 with some questions and “no” in others). The total score for the questionnaire is
0 to 30 with 0-9 showing no depression, 10-19 mild depression, and 20-30 severe
depression.
2.3.3 Zarit’s Caregiver Burden Scale (ZCBS)
The ZCBS is a widely used questionnaire measuring the level of burden felt by
caregivers (Parks & Novielli, 2000). The questionnaire contains 22 items which are
answered by using a Likert scale with 5 responses. The possible responses in order are
“never”, “rarely”, “sometimes”, “quite frequently”, and “nearly always” with each
answer scored from 0 to 4 respectively. The total score ranges from 0 to 88 with a score
between 0 and 22 indicating no burden, 23 to 44 mild burden, 45 to 66 moderate burden,
and 67 to 88 severe burden.

Clock Drawing: 8-Point Scoring
•
•
•
•
•
•
•
•

Correct Numbering (all numbers (1-12) included and no others).
Numbers in Correct Position
Numbers in Clock Circle
Numbers Spaced Relatively Equally Apart
Numbers Spaced Relatively Equal from Circle Edge
One Clock Hand Points to 2
One Clock Hand Points to 11
There are only 2 Clock Hands
Fig 1. Clock Drawing: 8-Point Scoring
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2.3.4 Clock Drawing Task: 8 Point Scoring (CDT-8)
Clock drawing has become a standard test for visuospatial problems in
individuals. The patient is asked to draw a clock with the hands pointing to 10 after 11.
The clock drawing portion of the Self Test II (STII) (de Leonni Stanonik et al., 2005) is
used to obtain the CDT-8. There have been a number of scoring methods suggested;
however the 8-point scoring was used for the study since it has been shown to highly
correlate with driver safety (U.S. Department of Transportation, 2000) (Fig 1).
2.3.5 Trail Making Test – Part B (TMT-B)
Numerous studies have been performed showing the TMT-B significantly
correlates to driver performance and safety (Stutts, Stewart, & Martell, 1998). The
questionnaire is an administered test and asks an individual to draw a continuous line
starting at the number 1 and ending with the letter L. The line has to alternate from the
next number in the sequence to the next letter and then again to the next number (1 to A,
A to 2, 2 to B, etc.). The person is corrected and helped by the administrator if mistakes
or confusion occurs. Not completing the test within 3 minutes indicates a higher chance
of being in a car accident or displaying poor performance on a driving test.
2.4 DATA COLLECTION PROCEDURES
2.3.4 AD Subject Data Collection
All patients and caregivers enrolled in the study were required to read and sign an
Informed Consent approved by the University of Tennessee Graduate School of Medicine
Institutional Review Board (IRB #2232) (Appendix C). The questionnaires administered
to each patient enrolled in the 43-item part of the study were the 43-Item CAS-AD,
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MMSE, and GDS. The caregiver was only asked to complete the caregiver version of the
CAS-AD. The questionnaires administered to each patient enrolled in the 10-item part of
the study were the 10-item CAS-AD, MMSE, GDS, CDT-8, and TMT-B. The caregiver
also filled out the ZCBS and the caregiver version of the CAS-AD. The MMSE, GDS,
TMT-B, CDT-8, and ZCBS were administered as part of the patient’s normal visit to the
Cole Neuroscience Center. The questionnaires are routinely administered to the majority
of the patients seen at the clinic. The MMSE and TMT-B were required to be
administered by staff at the Cole Neuroscience Center, while the GDS, CDT-8, and
ZCBS did not require any supervision by staff members. All questionnaires were scored
by the Cole Neuroscience staff or research assistants, except for the CAS-AD which was
scored using command syntax written in SPSS v16. The scores from the MMSE, GDS,
ZCBS, CDT-8, and TMT-B were recorded on a top sheet and attached to the patient’s
and caregiver’s completed CAS-AD questionnaires. All data collected was entered into
SPSS v16 where each subject was given a unique identifier to maintain subject privacy.
2.4.1 Normal Subject Data Collection
All normal subjects and caregivers enrolled in the study were required to read and
sign an Informed Consent approved by the University of Tennessee Graduate School of
Medicine Institutional Review Board (IRB #2232) (Appendix C). The questionnaires
administered to each subject enrolled in the MMSE and the 10-item CAS-AD. The
MMSE were required to be administered by investigators at the Cole Neuroscience
Center and University of Tennessee Sleep Center. All questionnaires were scored by the
Cole Neuroscience staff or research assistants, except for the CAS-AD which was scored
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Fig 2. Caring for People with Alzheimer's Disease: A Manual for Facility Staff
(Gwyther, 2001)
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using command syntax written in SPSS v16. All data collected was entered into SPSS
v16 where each subject was given a unique identifier to maintain subject privacy.
2.5 CAS-AD Development
2.5.1 43-Item CAS-AD Development
Two Physicians and 2 Research Associates with Masters in Experimental
Psychology developed the initial 43-item questionnaire. Item topics where based on the
observations of investigators while seeing patients at the Cole Neuroscience Center’s
Alzheimer’s clinic and adapted from a list of symptoms cited in Caring for People with
Alzheimer's Disease: A Manual for Facility Staff (Gwyther, 2001) (Fig. 2). The
symptoms listed by Gwyther have been accepted by the National Institute of Aging
(2007). Items created for the questionnaire were designed to reflect a broad range of
symptoms observed throughout the course of the disease.
The patient questionnaire had a seven page format. The caregiver questionnaire
had the same items as the patient form; however questions were reworded to ask about
the patient. Answers to items were closed ended using a 5-response Likert scale. The
possible responses were “Never”, “Almost Never”, “Sometimes”, “Almost Always”, and
“Always”. A response header was printed at the top and bottom of the page to remind
patients and caregivers of the 5 possible responses.
Administrators were asked to note recurring misunderstandings, confusion, or
frustrations with items with the first 30 patients and caregivers who completed the
questionnaire. Those items were reviewed and modified by the investigators, and the
questionnaire was updated to reflect any changes. An example would be “I often wander
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Fig 3. Portion of Original 43-Item Questionnaire Layout
without any purpose”. A number of patients loosely interpreted the question to mean “to
wander about with nothing to do” so the question was reworded to “I wander aimlessly”
which prevented any further confusion reported.
While administering the 43-item questionnaire, administrators also uncovered a
visuospatial problem with some AD patients not being able to correctly line up items to
the matching response line (Fig 3). To correct for the problem the questionnaire was
reformatted by placing a response header over every item and separating each
header/item with white space (Fig 4). This made it easier for participants to line up the
items with corresponding responses; however, it also caused the questionnaire to be
expanded to from 4 to 7 pages.
Once modifications were complete the questionnaire was administered to 23 new
patients who completed the questionnaire without assistance of an administrator. The
first 30 patients used for the development of the questionnaire were not included in the
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Fig 4. Portion of Revised 43-Item Questionnaire Layout
data analysis since the format of the questionnaire differed from that administered to
patients enrolled after changes in the questionnaire format.
2.5.2 Scoring the 43-Item CAS-AD
The 43-Item CAS-AD was scored by assigning a value of 1 to 5 respectively to
each item response (“Never”, “Almost Never”, “Sometimes”, “Almost Always”, and
“Always”). The absolute value of each patient’s item response score minus the
caregiver’s item response score was totaled. For the 43-Item scale the resulting score
was divided by 43 for a result of 0 to 4.
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2.5.3 10-Item CAS-AD Development
When sufficient data was collected the questionnaire’s internal reliability was
determined using Cronbach’s-alpha and item reduction of the 43-tiem questionnaire was
performed.
2.5.4 Scoring for the Administration of 10-Item CAS-AD to AD Subjects
For the 10-Item questionnaire the sum of the item scores were not divided by 10.
This resulted in a score of 0 to 40. The reason for using a different scoring method was
to allow for a score consisting of integers which are easily interpretable by individuals in
a clinic setting.
2.6 Statistical Analysis
All independent t-test were 2-tailed and used an alpha of 0.05. A distribution
would be considered normal if the skewness and kurtosis fell between the range of ±2
(George & Mallery, 2003).
2.6.1 Descriptive Statistics of 43-Item CAS-AD Administered to Preliminary AD
Subjects
Descriptive statistics were performed on the patient’s gender and age. The
patients were then divided into two groups by gender, and descriptive statistics for age
were obtained, as well as skewness and kurtosis to determine if the ages of each gender
were normally distributed. An independent t-test was used to determine if the ages
between genders were significantly different. A Leven’s Test of Equality of Variance
was used to determine if the age between genders were similar (Levene, 1960).

31

Descriptive statistics were performed on the 43-item questionnaire score for the
total group and for each gender. The descriptive statistics contained skewness and
kurtosis to determine if the scores were distributed normally. A Leven’s Test was used to
test the Equality of Variance of scores between genders and an independent t-test was
used to determine whether scores between genders were statistically different.
2.6.2 43-Item CAS-AD Reduction Analysis
Cronbach’s-alpha was used to determine the internal reliability of the
questionnaire. The analysis was then used to remove items from the questionnaire with
the goal of having a 10-item questionnaire displaying Cronbach’s-alpha between 0.8 and
0.9. Items were removed one at a time if their removal would keep the remaining items
Cronbach-alpha as close to 0.9 as possible. If there were two or more items whose
removal would result in the same Cronbach’s-alpha, the investigators removed the item
which was perceived as the least important to the content validity of the questionnaire.
The removal process was continued until only 10 items remained. The resulting 10 items
were rescored using the method described for the 43-item questionnaire and a Pearson’s
correlation coefficient (Rodgers, & Nicewander, 1988) was obtained to determine how
well the scores of the 43-item and 10-item questionnaire relate.
2.6.3 Descriptive Statistics for the Administration of 10-Item CAS-AD to AD
Subjects
Descriptive statistics were performed on the patient’s gender and age. The
patients were then divided into two groups by gender, and descriptive statistics for age
were obtained, as well as skewness and kurtosis to determine if the ages of each gender

32

were normally distributed. An independent t-test was used to determine if the ages
between genders were significantly different. A Leven’s Test of Equality of Variance
was used to determine if the age between genders were similar.
Descriptive statistics were performed on the 10-item questionnaire score for the
total group and for each gender. The descriptive statistics contained skewness and
kurtosis to determine if the scores were distributed normally. A Leven’s Test was used to
test the Equality of Variance of scores between genders and an independent t-test was
used to determine whether scores between genders were statistically different.
Reliability of the 10-item questionnaire was determined using three different
statistical methods. A Cronbach’s-alpha was performed to determine the internal
reliability of the questionnaire. A Pearson’s-r correlation coefficient was used to
determine test-retest reliability of the questionnaire and a One-way Intraclass Coefficient
(ICC) (Koch, 1982) was used to determine inter-rater agreement. A split-half reliability
analysis was use to obtain a spearman-brown coefficient for equal length parts (Brown,
1910); (Spearman, 1910).
Descriptive statistics for the MMSE, GDS, CDT-8, TMT-B, and ZCBS were
determined for the patient population and the population divided by gender. A Pearson’sr was used to determine if significant correlations exist between afore mentioned
questionnaires and the 10-item questionnaire score for the patient population total and by
gender. A 2-tailed independent t-test was performed for each questionnaire to determine
if any significant difference existed between genders.
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2.6.4 Descriptive Statistics for the Administration of 10-Item Questionnaire to
Normal Subjects
The statistical process used in section 2.6.1 was used to analyze the group of
normal subjects enrolled for the 10-item administration of the questionnaire. A 2-tail
independent t-test was performed for ages between the AD patients and normals who
took the 10-Item questionnaire to make sure the groups were of similar age (de Leonni
Stanonik, et al., 2005).
2.6.5 Analysis of AD Subjects with and without anosognosia based on Administered
10-item CAS-AD
A cutoff score for the 10-Item CAS-AD was determined to define anosognosia
among AD patients. The cutoff score was calculated as 2 SD above the mean of the
normal population. The 10-item AD group was divided into two groups; those without
and with anosognosia. A one-tail independent t-test was performed to determine if any
significantly lower mean score on the TMT-B existed for the group with anosognosia.
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3. RESULTS
3.1 Descriptive Statistics of 43-Item CAS-AD Administered to Preliminary AD
Subjects
One-hundred and six Alzheimer patients who met the inclusion criteria were
enrolled in the study. Thirty-nine were excluded due to incomplete questionnaires with
the final number being 67 (age: u = 72.66, SD = 3.40), with 41 females (age: u = 72.39,
SD = 4.58) and 26 males (age: u = 73.08, SD = 4.14). The age between genders showed
no significant difference existing (t(65) = 0.537, p = 0.593) (Table 4).
The 43-Item Questionnaire score for the population had a mean of 0.87 (SD =
0.42) with the mean score for females being .87 (SD = 0.42) and males .87 (SD = 0.36).
Since the kurtosis of the scores for females was 2.68 (female: median = 0.76, range =

Table 4. 43-Item Subject Statistics
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Table 5. 43-Item Subjects Statistics with 10-Item Scoring

Table 6. 10-Items After Item Reduction
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2.10; male: median = 0.81, range = 1.36) the scores were transformed using log10 to
create a normal distribution. The females mean was -0.10 (SD = 0.20) and males -0.10
(SD = 0.18). Using the transformed scores between genders equal no significant
difference was found (t(65) = 0.142, p = 0.887).
3.2 43-Item CAS-AD Reduction Analysis
The 43-item questionnaire had a Cronbach's-alpha of 0.89 was obtained showing
the questionnaire had excellent internal reliability. The 10-Items left after reduction were
scored using the sum of item scores divided by 10. The mean score was 1.10 (SD = 0.63)
with the mean score for females being 1.13 (SD = 0.64) and males 1.05 (SD =0.63). The
10-item scores between genders showed no significant difference (t(65) = -0.498, p =
0.620) (Table 5). The reduction of the questionnaire to 10-items produced a Cronbach’salpha of 0.84 (Table 6). A significantly high correlation (r =0.90, p < 0.000) was found
when the final 10 items identified were rescored and compared to the original 43-item
questionnaire scores.
3.3 The Administration of 10-Item CAS-AD to AD Subjects
Of the eighty-four new AD patients enrolled in the second phase of the study
using the 10-item questionnaire; one patient dropped out citing privacy concerns (Table
7). The total number of patients used was 83 (age: u = 75.53, SD = 3.83), with 58
females (age: u = 75.21, SD = 3.80) and 25 males (age: u = 76.28, SD = 3.89). The
patients age between genders showed no significant (t(81) = -1.176, p = 0.243). The
mean 10-item score was 12.94 (SD = 6.94), with females mean score of 12.81 (SD =
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7.21) and males 13.24 (SD = 6.39). The scores between genders showed no significant
difference (t(81) = -0.257, p = 0.798).
Internal reliability of the new questionnaire remained high with an obtained
Cronbach’s-alpha of 0.87 (Table 6). Nineteen of the 83 patients who each had 2
caregivers acting as informants were used to determine the inter-rater agreement. The
ICC single measure alpha was 0.63 (p < 0.000). Twenty-one of the 83 patients were
used to evaluate the test-retest over time using scores from initial enrollment and 3 month
follow up visit. Results showed a significantly high correlation (r = 0.70, p < 0.000).
Using the 83 patients split-half reliability was found to be significantly high (n = 83, r =
0.86, p < 0.000).
For the patient population the mean for the MMSE (u = 21.30, SD = 2.59), GDS
(u =6.29, SD = 4.93), CDT-8 (u = 5.12, SD = 2.58), and ZCBS (u = 29.37, SD = 17.36)
Mean scores for the questionnaires were obtained for females (MMSE: u = 21.10, SD =
2.75; GDS: u = 6.41, SD = 5.29; CDT-8: u = 4.83, SD = 3.32; ZCBS: u = 28.12, SD =
16.61), and males (MMSE: u = 21.76, SD = 2.17; GDS: u = 6.00, SD = 4.03; CDT-8: u
= 32.28, SD = 3.81; ZCBS: u = 5.80, SD = 2.63).
A significant differences was not found among male and female study patients for
any of the questionnaires (MMSE: t(81) = -1.06, p = 0.292; GDS: t(81) = 0.35, p >
0.728; CDT-8: t(81) = -1.00, p > 0.320; ZCBS: t(81) = -1.59, p > 0.116). Correlations
between the sample population 10-item questionnaire score and the MMSE (r = -0.24, p
= 0.032), and GDS (r = -0.30, p = 0.006) were significant though weak, where the
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Table 7. 10-Item Statistics: Administration to AD Subjects

correlation with the CDT-8 (r = -0.04, p = 0.743), and ZCBS (r = 0.04, p = 0.699)
showed no significance (Table 7).
3.4 Descriptive Statistics for the Administration of 10-Item CAS-AD to Normal
Subjects
There were 43 normal subjects enrolled in the study (age: u = 73.95, SD = 3.90) with 23
females (age: u = 73.83, SD = 4.23) and 20 males (u = 74.10, SD = 3.60). Age between
genders showed no significant difference (t(41) = 0.227, p = 0.822) (Table 8). The mean
MMSE score for the sample population was 29.67 (SD = 0.75). The distribution does not
have a normal curve, however this is expected since the MMSE scores of the normal
population are expected to not have adequate variance. The age between the AD Patients
administered the 10-item questionnaire and normal subjects showed no significant
39

Table 8. Normal Subject Statistics

Table 9. Statistics for Patients Defined With and Without Anosognosia

40

difference in age. The ages between groups had unequal variance (F = 15.330, p <
0.000), with the t-test result for unequal variance showing significant difference in age
between groups (t(123.68) = 1.778, p = 0.078). The mean CAS-AD score for the normal
subjects was 7.19 (SD = 2.22) with females having a mean of 7.26 (SD = 2.24) and males
7.10 (SD = 2.25). No significant difference in scores was found when comparing
between gender (t(41) = -0.235, p = 0.816).
3.5 Analysis of AD Subjects with and without anosognosia based on Administered
10-item CAS-AD
Using the mean and SD of the normal subjects a cutoff score to define anosognosia was
determined to be 12. There were 41 (49%) patients who did not fit the definition for
anosognosia (age: u = 74.23, SD = 8.05) and 42 (51%) with anosognosia (age: u = 77.41,
SD = 7.73). The age between the groups with and without anosognosia showed no
significant difference (t(81) = -1.839, p = 0.070) (Table 9).
For patients without anosognosia the mean score for the MMSE was 21.46 (SD =
2.51), GDS was 7.54 (SD = 7.54), ZCBS was 28.95 (SD = 18.01), and CDT-8 was 5.00
(SD = 2.48). For patients with anosognosia the mean score for the MMSE was 21.14 (SD
= 2.68), GDS was 5.12 (SD = 3.78), ZCBS was 31.12 (SD = 17.26), and CDT-8 was 5.19
(SD = 2.70).
Unequal variance was found between patient groups with and without anosognosia for
GDS scores (F = 7.657, p = 0.007). Patients without anosognosia had a significantly
greater GDS score then patients without anosognosia (t(69.24) = 2.273, p = 0.026). The
MMSE ((t(81) = 0.562, p = 0.576), ZCBS ((t(81) = -0.560, p =.577), and CDT-8 ((t(81)
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Table 10. Statistics for TMT-B Grouped by With and Without Anosognosia

= -0.335, p = 0.738) showed no significant differences in mean scores between patients
with and without anosognosia.
There were 22 patients willing to complete the TMT-B, ten of which did not meet
the criteria for anosognosia (Table 10). Ten were without anosognosia (age: u = 74.00,
SD = 6.37) and 12 with (age: u = 77.33, SD = 8.55). Age between patients with and
without anosognosia showed no significant difference (t(20) = -1.018, p = 0.321). The
mean scores for the TMT-B for patients without anosognosia was 16.67 (SD = 5.55) and
with was 14.70 (SD = 5.95) with no significant difference existing (t(20) = -0.802, p =
0.432).
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4. DISCUSSION
4.1 43-Item CAS-AD
The CAS-AD was begun in 2001 as a companion questionnaire for an fMRI
imaging investigation into the possible role the anterior cingulate cortex (ACC) plays in
the area of attention and self awareness (Stanonik, 2002). The study consisted of normal
controls and AD patients. The AD patients were further divided into with and without
anosognosia groups using the 43-Item CAS-AD with a cutoff point of 1. Anosognosia
was used as a means of distinguishing subjects who had a deficit of self awareness and
the MRI images obtained were analyzed to determine if the ACC activation was
significantly different in the Anosognosia subject when compared to the other groups (the
study found a significant hypoactivation in the anosognosia group).
At the time of the 2001 study a questionnaire called the Anosognosia
Questionnaire for Dementia (AD-Q) (Migliorelli et al., 1995) was going to be used which
had been developed for an fMRI study performed in Argentina. After reviewing the
material there was concern with problems in translation of the questions since every item
was preceded with the negative sounding phrase “Do you have problems”. This concern
prompted the investigators to administer the questionnaire to several patients to evaluate
how individual’s felt about the questions. It was concluded by the investigators that the
patients were feeling potential levels of anxiety due to the questionnaire’s wording and it
was the desire of the investigators to minimize as much stress as possible. The
investigators decided not to use the AD-Q and instead create a questionnaire for use in
the study with specific care taken to make it as minimally evasive as possible.
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4.2 Subject Selection for 43-Item and 10-Item CAS-AD
The inclusion and exclusion criteria for the study were a carry over of the original
2001 fMRI study. Due to the nature of the study, the criteria were more rigid than
necessary for the psychometric testing and should have been changed in order to include
a more culturally diverse group of subjects. The removal of the MMSE score
requirements and whether the patient had past psychological disorders would have
allowed for the study to be generalized to a larger AD population and increase the
statistical power of the study, though it would have added numerous confounding
variables.
Another limiting factor to the number of individuals included in the study was the
active clinic setting where the data was collected. Data collection occurred during patient
visits to the office which limited the time available to administer questionnaires not
specific to a patient’s visit. The Cole Neuroscience Center does not have a diverse socioeconomic or minority population. The current study’s population exclusively contained
Caucasians. Both of these factors put into question the validity of the questionnaire in the
general population, though the simplicity of the questionnaire’s items should allow it to
span across ethnic groups and education levels.
4.3 43-Item CAS-AD
The items used were meant to capture a broad spectrum of symptoms seen
throughout the 3 stages of the AD Mild, Moderate, and Severe. The item creation
method used could bring into question the face validity of the questionnaire. Another
method would have been to poll the caregiver population to determine common recurring
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symptoms and concerns (Streiner & Norman, 1995). To perform data collection in the
following manner would have required additional time which was not conducive to the
time constraints of the initial ACC study. Nevertheless, the items came from reliable
sources and are believed to have adequately reflected common caregiver observations. In
order to show internal reliability a Cronbach's-alpha between 0.8 and 0.9 is desired
(George & Mallery, 2003). The internal reliability of the questionnaire was high (r =
0.89) showing a significant degree of association between the items.
Though the 43-Item questionnaire could be used on its own, it was the intention
of the investigators to create a more accessible 10-Item scale for both research and
clinical settings. The significantly strong correlation (r = 0.90) between the 43-tiem and
10-item version of the instrument demonstrates the shorter version is as reliable as its
longer version. This allows the shorter version to be ideal for setting where it is
important for a questionnaire to be administered in a timely manner.
4.4 10-Item CAS-AD
After being administered to a new sample AD patients the internal reliability of
the 10-Item questionnaire remained high (cronbach’s-alpha = 0.87) showing the items
related well to each other while maintaining adequate variability. The questionnaire
allows for anosognosia to be measured in two different ways. First, the score can be used
as a measurement of the degree of anosognosia on a continuum. Second, the
questionnaire can be used to diagnose anosognosia in the AD patient by using the cutoff
score of 12.
As expected, when using the entire sample population there was a statistically
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significant, but small correlations found between the total 10-Item CAS-AD and the
MMSE (r = -0.24, p < 0.05) or GDS (r = -0.30, p < 0.05). Though some prior research
has shown anosognosia to have a high correlation with cognitive decline and depression
(but not necessarily with both together)( Sevush & Leve, 1993), it is believed that
anosognosia is its own unique phenomena which is not related to degree of dementia or
depression ((Feher, Mahurin, Inbody, Crook, & Pirozzolo, 1991); (Reed, Jagust, &
Coulter, 1993). The low correlation adds credence to this hypothesis.
To asses the stress associated with caregivers a correlation of the ZCBS was
performed using the 10-Item questionnaire AD population with no significant correlation
being found (r = -0.04, p = 0.699). The opposite results were expected with caregiver
stress increasing as the severity of anosognosia increased. It is expected that the results
may be a function of the inclusion criteria using the MMSE score. Excluded from the
study were patients with more severe dementia. It is hypothesized caregivers of subjects
with more pronounced dementia may increase the mean of the stress for the group with
anosognosia and a significant difference would be found. Furthermore, it uncertain if the
high level of social work intervention provided at Cole Neuroscience Center may be
adding a confounding variable in regard to caregiver stress.
4.5 Inter-rater and Test-retest Reliability of 10-Item CAS-AD
The resulting ICC for the questionnaire was high (r = 0.63, p < 0.05), but a result
greater then 0.70 is desired. Though not as high as hoped for it is considered to be
satisfactory given the nature of the caregivers which are being used in the study. AD
patients who attended the clinic with more then one caregiver would have a spouse and a
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child with them. The varying contact the caregivers might have with the patient is a
confounding factor which could have caused a discrepancy, there by lowering the ICC
result.
Results of test-retest analysis among patients yielded a Pearson-r correlation of
0.70 (p < 0.000). Like the ICC, this is not as high as would be desired, but good enough
to be able to say with confidence that the questionnaire was reliable when administered
over time. The target period used was 3 months; however one of the factors which could
not be accounted for was the use of pharmaceutical medication during the test-retest
period which may increase or maintain a patient’s cognitive ability. Though denying
drug therapy would be the best way to perform test-retest reliability, it would be unethical
to deny treatment.
4.5 AD Subjects with and without anosognosia as Diagnosed by 10-Item CAS-AD
There was no significant difference in age between the AD subjects and normals
who took the 10-Item questionnaire (t(123.68) = 1.78, p > 0.05) which increases the
confidence that the normal group appropriately reflected the ages of AD group and
allowed for the setting of the cutoff score based on the normals mean and SD (de Leonni
Stanonik, et al., 2005).
Fifty-one percent of the AD subjects had anosognosia (n = 42) when using the
cutoff score of 12. The prevalence of anosognosia among study patients is approximately
midway between the reported numbers of 20% to 75% (Migliorelli, et al., 1995);
(Antoine, Antoine, Guermonprez, & Frigard, 2004)
Depression scores between AD subjects with and without anosognosia showed
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that subjects with anosognosia had a significantly lower level of depression (t(69.24) =
2.27, p < 0.05). The result was unexpected, but it does show that anosognosia may have
a relationship with the levels of patient depression, stressing the importance of the low,
but significant correlation between depression scores and the 10-item score of the 83 AD
subjects.
Driving
Driving is one of the activities essential to the independent life style of most
individuals today. There is a noticeable decrease in driving skill as people age and the
effects are worsened with the advent of dementia (U.S. Department of Transportation,
2000). Even though in mild AD patients there is still an ability to control vehicles, they
are at increased risk of getting lost, making incorrect turns, and causing at-fault errors on
driving simulation tasks (Uc, Rizzo, Anderson, Shi, & Dawson, 2004).
It is important in the management of an AD patient to limit, or even better, cease
driving. Since driving is so empowering to an individual’s sense of independence it often
becomes difficult to get compliance (Steven W Anderson, Rizzo, Shi, Uc, & Dawson,
2005). Research by Freund and associates (2005) showed elderly drivers without
dementia who considered themselves better than other drivers their age were over four
times more likely to be unsafe drivers when compared to those who rate themselves as
being comparable to or worse than other drivers of their age. Freund specifically points
out the problem in determining why the unsafe drivers may over rate their abilities.
Though a lack of awareness was mentioned the study was not designed to determine
anosognosia was a factor. Nevertheless, even though the subjects of the study did not
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have AD or other dementias, it still manages to underscore the importance of AD patients
ceasing driving activities.
Important for caregivers to understand is anosognosia does not relieve the patient
or their estate of legal liability in the event of a driving accident. In every state public
policy forces persons with disabilities to pay for damage they do if they “are to live in the
world.” The policy clearly indicates how a lack of awareness of driving ability does not
break the chain of causation in a liability suite, thereby causing eliminating anosognosia
as a valid defense.
The CDT-8 and TMT-B are used to measure driver safety with low scores in both
indicating decreased driver ability. Using the entire study sample, the CDT-8 showed no
slightly negative, non-significant correlation to the anosognosia scores (r = -0.04, p >
0.05). The t-tests comparing AD subjects with and without anosognosia on the TMT-B
produced no significant results (t(20) = 0.43, p > 0.05), though the sample size used for
the test was relatively small (with anosognosia: n = 10, u = 14.70, SD = 5.945; without
anosognosia: n = 12, u = 16.67, SD = 5.549).
The low negative correlation with the MMSE and the 10-item questionnaire
scores administered to AD patients might mean anosognosia occurs independently of
cognitive decline which would make the CDT-8 and TMT-B results expected. Further
research would need to be performed with more sensitive testing, such as a driving
simulator. Though the questionnaire could not be used to make any definitive statement
about an AD patient’s ability to drive the results would still be beneficial for a clinician to
better inform caregivers of the inability of a patient to assess their limitations to drive a
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car safely.
4.6 Conclusion
Though anosognosia can be viewed as existing on a continuum it was shown
through the use of normal subjects that a cutoff value could be identified. This allows for
the scoring of the questionnaire to accurately diagnose a patient as having anosognosia.
The study lacked sufficient sample sizes to come to definitive conclusions about
the reliability of the questionnaire. Yet the lack of or significantly low correlations of the
10-item questionnaire scores for the patients (n = 83) with the other questionnaires
administered shows the questionnaire is measuring a separate and unique factor
associated with AD. Further investigation should include a larger sample size, have
greater control over collecting return data and include a greater number of patients with
multiple caregivers. In addition, the inclusion/exclusion criteria should be relaxed,
allowing for a sample population reflective of most of the population seen at clinics. A
comparison of the 43-Item and 10-Item questionnaire would be of interest to determine if
questionnaire format has any effect on score outcomes.
The CAS-AD questionnaire is unique since it was designed specifically for the
study of patients with AD and not all dementias. It has gone through more rigorous
psychometric testing then previous questionnaires. In the past, investigators have
developed questionnaires based on the need of an ongoing study and no attempt has been
made to assess the reliability or validity of the questionnaire. This situation has resulted
in numerous studies that can not be easily compared to one another since it is uncertain if
they are measuring the same phenomena. The 10-Item CAS-AD offers investigators a
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more accurate way to study AD related anosognosia by using a single reliable
questionnaire for diagnosis. The value of the questionnaire within the clinic comes from
its ease of administration and the assistance it can give to physicians and social workers
in estimating to caregivers the extent of the patient’s inability to properly gauge their
activities.
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